Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma

Published: 2025-03-17 07:09:49 ET CATX

March 17 (Reuters) - Perspective Therapeutics Inc :

* PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH VMT01 IN COMBINATION WITH NIVOLUMAB IN A PHASE 1/2A STUDY OF MC1R-POSITIVE METASTATIC MELANOMA Source text: Further company coverage: